Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 26.
doi: 10.1007/s10384-025-01211-5. Online ahead of print.

Five-year effect of sequential argon-Nd:YAG prophylactic laser peripheral iridotomy on corneal endothelial cell density in Japanese eyes with narrow angles

Koichi Mishima  1   2 , Naomi Mataki  3   4 , Hiroshi Murata  5   4 , Shinichiro Ohtani  6 , Hiroshi Sakai  7 , Atsuo Tomidokoro  8 , Makoto Aihara  4 , Kazunori Miyata  6 , Aiko Iwase  3 , Makoto Araie  9
Affiliations

Five-year effect of sequential argon-Nd:YAG prophylactic laser peripheral iridotomy on corneal endothelial cell density in Japanese eyes with narrow angles

Koichi Mishima et al. Jpn J Ophthalmol. .

Abstract

Purpose: To evaluate the effects of prophylactic sequential argon- Nd:YAG laser peripheral iridotomy (pLPIsequential) on the corneal endothelial cell density (CECD) over 5 years in Japanese eyes with narrow angles (NA-eyes).

Study design: Prospective observational study METHODS: The CECD of NA-eyes before and after pLPIsequential and of untreated NA-eyes were assessed annually over 5 years with non-contact specular microscopy. Routine ophthalmic examinations and measurements using anterior-segment imaging devices were performed at baseline. The time courses of the CECD were analyzed using a multivariable linear mixed-effect model and factors obtained at baseline.

Results: Sixty-nine pLPIsequential-treated NA-eyes (69 subjects; mean age, 68.9 years) and 67 pLPIsequential-untreated NA-eyes (67 subjects; mean age, 64.4 years) were enrolled. In the pLPIsequential-untreated NA-eyes, no baseline factors were correlated significantly with the time course of the CECD, and its decline rate - 4.7 (95% Confidence interval (I: - 13.3 to 4.0) cells/mm2 was not significant (p = 0.267). In the pLPIsequential-treated NA-eyes, the CECD declined with marginal significance - 12.2 (- 24.7 to 0.3) cells/mm2/year (p = 0.0513) over 5 years. Higher laser energy used, thicker iris, and shallower central anterior chamber depth (cACD) at baseline were significantly negatively correlated with the post-laser CECD (p = 0.0092, 0.0119, and 0.0158). No significant difference was seen in the baseline factors-adjusted CECD decline rate (p = 0.262) between both the groups.

Conclusion: Prophylactic sequential argon-Nd:YAG pLPIsequential had no clinically significant effects on the time course of the CECD over 5 years in Japanese NA eyes. However, higher laser energy used, thicker iris, and shallower cACD significantly negatively affected the post-laser CECD.

Keywords: Corneal endothelial cell; Narrow angle; Sequential argon-Nd:YAG laser peripheral iridotomy.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: K. Mishima, None; N. Mataki, None; H. Murata, None; S. Ohtani, None; H. Sakai, Patents planned, issued or pending (TOMEY, the author receives no royalties); A. Tomidokoro, None; M. Aihara, Grants or contracts (Alcon, Santen, Senju, Otsuka, Kowa, Johnson & Johnson, Wakamoto, Tomey), Consulting fees (Santen, Senju, Otsuka, Kowa, CREWT Medical Systems, HOYA, Allergan, Wakamoto, Glaukos, Sato), Payment or honoraria for lectures (Alcon, Santen, Kowa, Senju, Otsuka, Viatris, Rohto Nitten, Kowa, HOYA, Johnson & Johnson, Wakamoto, Novartis, Glaukos, TOMEY, Topcon, ZEISS); K. Miyata, Grants or contracts (Alcon, AbbVie, Senju, Otsuka, Wakamoto, SEED, HOYA, AMO, MZ-science, BVI Medical), Payment or honoraria for lectures (Alcon, Santen, Kowa, Senju, Otsuka, AMO, HOYA, CUORE, Bayer, AbbVie, BVI Medical, Novartis, Menicon, AURION BIOTECH, LUMENIS, NIDEK), Patents planned, issued or pending (TOMEY, the author receives no royalties); A. Iwase, Consulting fees (Santen), Payment or honoraria for lectures (ZEISS, CREWT Medical Systems, Heidelberg Engineering, Santen, Senju, Otsuka, Topcon), Patents planned, issued or pending (Topcon, the author receives no royalties); M. Araie, licenses (Topcon, the author receives no royalties), Consulting fees (Santen, Senju, Aerie, Kowa), Payment or honoraria for lectures (Otsuka, Senju, Kowa, Santen), Patents planned, issued or pending (JGSTK-DiscAnalysis, the author receives no royalties).

Similar articles

See all similar articles

References

    1. Tham Y-C, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040. Ophthalmology. 2014;121:2081–90. - PubMed - DOI
    1. Day AC, Baio G, Gazzard G, Bunce C, Azuara Blanco A, Munoz B, et al. The prevalence of primary angle closure glaucoma in European derived populations: a systematic review. Br J Ophthalmol. 2012;96:1162–7. - PubMed - DOI
    1. Nakamura Y, Tomidokoro A, Sawaguchi S, Sakai H, Iwase A, Araie M. Prevalence and causes of low vision and blindness in a rural southwest island of Japan. The Kumejima Study Ophthalmology. 2010;117:2315–21. - PubMed - DOI
    1. Stein JD, Kim DS, Niziol LM, Talwar N, Nan B, Musch DC, et al. Differences in rates of glaucoma among Asian Americans and other racial groups, and among various Asian ethnic groups. Ophthalmology. 2011;118:1031–7. - PubMed - DOI
    1. Cho H-K, Kee C. Population-based glaucoma prevalence studies in Asians. Surv Ophthalmol. 2014;59:434–47. - PubMed - DOI

LinkOut - more resources